Clinical Trial Update: Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial comparing nepafenac ophthalmic suspension 0.1% with Acular LS for treatment of inflammation after cataract surgery has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract

Drugs mentioned

• ACULAR LS (Ketorolac tromethamine)
• Nevanac (nepafenac)

Snippet

Sponsor: Alcon Research | Conditions: Cataract | Phase 3 | Status: COMPLETED